For research use only. Not for therapeutic Use.
Vincristine sulfate（Cat No.:A001110）is a chemotherapy drug derived from the Madagascar periwinkle plant (Catharanthus roseus). It is a vinca alkaloid that works by inhibiting microtubule formation in the mitotic spindle, effectively halting cell division and leading to cell death. Vincristine is widely used in the treatment of various cancers, including leukemia, lymphoma, and solid tumors. Its ability to disrupt the cell cycle makes it a powerful anticancer agent. Vincristine sulfate is commonly employed in combination chemotherapy regimens, enhancing its efficacy while targeting rapidly dividing cancer cells.
| Catalog Number | A001110 |
| CAS Number | 2068-78-2 |
| Synonyms | Leurocristine |
| Molecular Formula | C46H56N4O10 • H2SO4 |
| Purity | ≥95% |
| Target | Microtubule/Tubulin |
| Solubility | >46.2mg/mL in DMSO |
| Storage | 3 years -20C powder |
| IUPAC Name | methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate;sulfuric acid |
| InChI | InChI=1S/C46H56N4O10.H2O4S/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6;1-5(2,3)4/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3;(H2,1,2,3,4)/t28-,37+,38-,39-,42+,43-,44-,45+,46+;/m1./s1 |
| InChIKey | AQTQHPDCURKLKT-JKDPCDLQSA-N |
| SMILES | CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O |
| Reference | </br>1:Hyaluronic acid-coated cationic nanostructured lipid carriers for oral vincristine sulfate delivery. Gao X, Zhang J, Xu Q, Huang Z, Wang Y, Shen Q.Drug Dev Ind Pharm. 2017 Apr;43(4):661-667. doi: 10.1080/03639045.2016.1275671. Epub 2017 Jan 8. PMID: 28043185 </br>2:The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate. Zhang J, Chen Y, Li X, Liang X, Luo X.Int J Nanomedicine. 2016 Aug 26;11:4187-97. doi: 10.2147/IJN.S109547. eCollection 2016. PMID: 27616886 Free PMC Article</br>3:Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia. Douer D.Oncologist. 2016 Jul;21(7):840-7. doi: 10.1634/theoncologist.2015-0391. Epub 2016 Jun 21. Review. PMID: 27328933 </br>4:Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias. Shah NN, Merchant MS, Cole DE, Jayaprakash N, Bernstein D, Delbrook C, Richards K, Widemann BC, Wayne AS.Pediatr Blood Cancer. 2016 Jun;63(6):997-1005. doi: 10.1002/pbc.25937. Epub 2016 Feb 17. PMID: 26891067 </br>5:Vincristine sulfate loaded dextran microspheres amalgamated with thermosensitive gel offered sustained release and enhanced cytotoxicity in THP-1, human leukemia cells: In vitro and in vivo study. Thakur V, Kush P, Pandey RS, Jain UK, Chandra R, Madan J.Mater Sci Eng C Mater Biol Appl. 2016 Apr 1;61:113-22. doi: 10.1016/j.msec.2015.12.015. Epub 2015 Dec 12. PMID: 26838831 </br>6:Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. Shah NN, Cole DE, Lester-McCully CM, Wayne AS, Warren KE, Widemann BC.Invest New Drugs. 2016 Feb;34(1):61-5. doi: 10.1007/s10637-015-0311-x. Epub 2015 Dec 10. PMID: 26661090 </br>7:Delivery of vincristine sulfate-conjugated gold nanoparticles using liposomes: a light-responsive nanocarrier with enhanced antitumor efficiency. Liu Y, He M, Niu M, Zhao Y, Zhu Y, Li Z, Feng N.Int J Nanomedicine. 2015 Apr 22;10:3081-95. doi: 10.2147/IJN.S79550. eCollection 2015. PMID: 25960649 Free PMC Article</br>8:Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT). Hantrakul S, Klangkaew N, Kunakornsawat S, Tansatit T, Poapolathep A, Kumagai S, Poapolathep S.J Vet Med Sci. 2014 Dec;76(12):1549-53. doi: 10.1292/jvms.14-0180. Epub 2014 Aug 21. PMID: 25649934 Free PMC Article</br>9:Validation of an UPLC-MS-MS Method for Quantitative Analysis of Vincristine in Human Urine After Intravenous Administration of Vincristine Sulfate Liposome Injection. Yang F, Wang H, Hu P, Jiang J.J Chromatogr Sci. 2015 Jul;53(6):974-8. doi: 10.1093/chromsci/bmu164. Epub 2014 Dec 17. PMID: 25520304 </br>10:Preparation of vincristine sulfate-loaded poly (butylcyanoacrylate) nanoparticles modified with pluronic F127 and evaluation of their lymphatic tissue targeting. Tan R, Niu M, Zhao J, Liu Y, Feng N.J Drug Target. 2014 Jul;22(6):509-17. doi: 10.3109/1061186X.2014.897708. Epub 2014 Mar 13. PMID: 24625287 |
